TY - JOUR
T1 - Congenital fibrinogen disorders
T2 - a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
AU - Mohsenian, Samin
AU - Palla, Roberta
AU - Menegatti, Marzia
AU - Cairo, Andrea
AU - Lecchi, Anna
AU - Casini, Alessandro
AU - Neerman-Arbez, Marguerite
AU - Asselta, Rosanna
AU - Scardo, Sara
AU - Siboni, Simona Maria
AU - Blatny, Jan
AU - Zapletal, Ondrej
AU - Schved, Jean Francois
AU - Giansily-Blaizot, Muriel
AU - Halimeh, Susan
AU - Daoud, Mohamad Ayman
AU - Platokouki, Helen
AU - Pergantou, Helen
AU - Schutgens, Roger E.G.
AU - Van Haaften-Spoor, Monique
AU - Brons, Paul
AU - Laros-Van Gorkom, Britta
AU - Van Pinxten, Elise
AU - Borhany, Munira
AU - Fatima, Naveena
AU - Mikovic, Danijela
AU - Saracevic, Marko
AU - Özdemir, Gül Nihal
AU - Ay, Yılmaz
AU - Makris, Michael
AU - Lockley, Caryl
AU - Mumford, Andrew
AU - Harvey, Andrew
AU - Austin, Steve
AU - Shapiro, Amy
AU - Williamson, Adrianna
AU - McGuinn, Catherine
AU - Goldberg, Ilene
AU - De Moerloose, Philippe
AU - Peyvandi, Flora
N1 - Publisher Copyright:
© 2024 by The American Society of Hematology.
PY - 2024/3/26
Y1 - 2024/3/26
N2 - Congenital fibrinogen deficiency (CFD) is a rare bleeding disorder caused by mutations in FGA, FGB, and FGG. We sought to comprehensively characterize patients with CFD using PRO-RBDD (Prospective Rare Bleeding Disorders Database). Clinical phenotypes, laboratory, and genetic features were investigated using retrospective data from the PRO-RBDD. Patients were classified from asymptomatic to grade 3 based on their bleeding severity. In addition, FGA, FGB, and FGG were sequenced to find causative variants. A total of 166 CFD cases from 16 countries were included, of whom 123 (30 afibrinogenemia, 33 hypofibrinogenemia, 55 dysfibrinogenemia, and 5 hypodysfibrinogenemia) were well characterized. Considering the previously established factor activity and antigen level thresholds, bleeding severity was correctly identified in 58% of the cases. The rates of thrombotic events among afibrinogenemic and hypofibrinogenemic patients were relatively similar (11% and 10%, respectively) and surprisingly higher than in dysfibrinogenemic cases. The rate of spontaneous abortions among 68 pregnancies was 31%, including 86% in dysfibrinogenemic women and 14% with hypofibrinogenemia. Eighty-six patients received treatment (69 on-demand and/or 17 on prophylaxis), with fibrinogen concentrates being the most frequently used product. Genetic analysis was available for 91 cases and 41 distinct variants were identified. Hotspot variants (FGG, p.Arg301Cys/His and FGA, p.Arg35Cys/His) were present in 51% of dysfibrinogenemia. Obstetric complications were commonly observed in dysfibrinogenemia. This large multicenter study provided a comprehensive insight into the clinical, laboratory, and genetic history of patients with CFDs. We conclude that bleeding severity grades were in agreement with the established factor activity threshold in nearly half of the cases with quantitative defects.
AB - Congenital fibrinogen deficiency (CFD) is a rare bleeding disorder caused by mutations in FGA, FGB, and FGG. We sought to comprehensively characterize patients with CFD using PRO-RBDD (Prospective Rare Bleeding Disorders Database). Clinical phenotypes, laboratory, and genetic features were investigated using retrospective data from the PRO-RBDD. Patients were classified from asymptomatic to grade 3 based on their bleeding severity. In addition, FGA, FGB, and FGG were sequenced to find causative variants. A total of 166 CFD cases from 16 countries were included, of whom 123 (30 afibrinogenemia, 33 hypofibrinogenemia, 55 dysfibrinogenemia, and 5 hypodysfibrinogenemia) were well characterized. Considering the previously established factor activity and antigen level thresholds, bleeding severity was correctly identified in 58% of the cases. The rates of thrombotic events among afibrinogenemic and hypofibrinogenemic patients were relatively similar (11% and 10%, respectively) and surprisingly higher than in dysfibrinogenemic cases. The rate of spontaneous abortions among 68 pregnancies was 31%, including 86% in dysfibrinogenemic women and 14% with hypofibrinogenemia. Eighty-six patients received treatment (69 on-demand and/or 17 on prophylaxis), with fibrinogen concentrates being the most frequently used product. Genetic analysis was available for 91 cases and 41 distinct variants were identified. Hotspot variants (FGG, p.Arg301Cys/His and FGA, p.Arg35Cys/His) were present in 51% of dysfibrinogenemia. Obstetric complications were commonly observed in dysfibrinogenemia. This large multicenter study provided a comprehensive insight into the clinical, laboratory, and genetic history of patients with CFDs. We conclude that bleeding severity grades were in agreement with the established factor activity threshold in nearly half of the cases with quantitative defects.
UR - http://www.scopus.com/inward/record.url?scp=85188776419&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2023012186
DO - 10.1182/bloodadvances.2023012186
M3 - Article
C2 - 38286442
AN - SCOPUS:85188776419
SN - 2473-9529
VL - 8
SP - 1392
EP - 1404
JO - Blood Advances
JF - Blood Advances
IS - 6
ER -